Prospective mapping of viral mutations that escape antibodies used to treat COVID-19
Open accessPublished version of a preprint
The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Abstract
Mapping antibody escape in SARS-CoV-2: Several antibodies are in use or under development as therapies to treat COVID-19. As new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants emerge, it is important to predict whether they will remain susceptible to antibody treatment. Starr et al. used a yeast library that covers all mutations to the SARS-CoV-2 receptor-binding domain that do not strongly disrupt binding to the host receptor (ACE2) and mapped how these mutations affect binding to three leading anti–SARS-CoV-2 antibodies. The maps identify mutations that escape antibody binding, including a single mutation that escapes both antibodies in the Regeneron antibody cocktail. Many of the mutations that escape single antibodies are circulating in the human population. Science , this issue p. 850
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

![Fig. 2 Escape maps are consistent with viral mutations selected in cell culture and a persistently infected patient. (A) Viral escape mutations selected by Regeneron with spike-pseudotyped VSV in cell culture in the presence of antibody (12). (B) Escape maps like those in Fig. 1A, but showing only mutations accessible by single-nucleotide changes to the Wuhan-Hu-1 sequence, with nongray colors indicating mutations in cell culture (red), the infected patient (blue), or both (purple). Figure S5 shows these maps colored by how mutations affect ACE2 affinity or RBD expression. (C) Dynamics of RBD mutations in a patient treated with REGN-COV2 at day 145 of infection (black dot-dash vertical line). E484A rose in frequency in linkage with F486I, but because E484A is not an escape mutation in our maps, it is not shown in other panels. See also fig. S4. (D) The escape mutations that arise in cell culture and the infected patient are single-nucleotide–accessible and escape antibody binding without imposing a large cost on ACE2 affinity [as measured using yeast display (7)]. Each point is a mutation, with shape and color indicating whether it is accessible and selected during viral growth. Points farther to the right on the x axis indicate stronger escape from antibody binding; points higher up on the y axis indicate higher ACE2 affinity.](https://figures.cochat.ai/paper-figures/91cf075ab18741e0a80bfb01ad2b708a/prospective-mapping-of-viral-mutations-that-escape-antibodies-used-to-treat-figure-2.jpg)

![Fig. 4 Structural context of escape mutations. (A) Escape maps projected on antibody-bound RBD structures. [REGN10933 and REGN10987: Protein Data Bank (PDB) ID 6XDG (11); LY-CoV016: PDB ID 7C01 (13)]. Antibody heavy- and light-chain variable domains are shown as blue cartoons, and the RBD surface is colored to indicate how strongly mutations at that site mediate escape (white indicates no escape, red indicates strongest escape site for that antibody or cocktail). Sites where no mutations are functionally tolerated are colored gray. (B) For each antibody, sites were classified as direct antibody contacts (non-hydrogen atoms within 4 Å of antibody), antibody-proximal (4 to 8 Å), or antibody-distal (>8 Å). Each point indicates a site, classified as escape (red) or non-escape (black). The dashed gray line indicates the cutoff used to classify sites as escape or non-escape (see materials and methods for details). Red and black numbers indicate how many sites in each category are escape or non-escape sites, respectively. Interactive visualizations are at https://jbloomlab.github.io/SARS-CoV-2-RBD_MAP_clinical_Abs/, and hypothesized mechanisms of escape and additional structural details for labeled points are shown in fig. S6.](https://figures.cochat.ai/paper-figures/854cbba408614d74b93381682c26dd9e/prospective-mapping-of-viral-mutations-that-escape-antibodies-used-to-treat-figure-4.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A475V is resistant to class 1 antibodies (structurally defined as described29); E484K and Q493R are resistant to class 2 antibodies7,8,12,13,29,30,32,33; while R346S, N439K, and N440K are resistant to class 3 antibodies7,8,12,13,29,33.”
From mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants (2021) · cites this paper as [32]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Several of the RBD mutations directly affect angiotensin-converting enzyme 2 (ACE2) receptor-binding affinity, which may affect infectivity, viral load, or transmissibility.11, 12, 13, 14”
From Impact of SARS-CoV-2 variants on the total CD4+ and CD8+ T cell reactivity in infected or vaccinated individuals (2021) · cites this paper as [12]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Mutations found in emergent S variants decrease sensitivity to neutralization by mAbs, convalescent plasma, and sera from vaccinated individuals (27, 37, 58, 61–70).”
From mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection (2021) · cites this paper as [58]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The B.1.1.7, B.1.351, and P.1 lineages all harbor a N501Y mutation in the RBD, which increases the affinity for the ACE2 receptor (57, 58), and a D614G mutation, which increases virion spike density, infectivity, and transmissibility (59, 60).”
From mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection (2021) · cites this paper as [58]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“We tested four clinically approved monoclonal antibodies that target the RBD 18,19 (bamlanivimab (LY-CoV555), etesevimab (LY-CoV016), casirivimab (REGN10933) and imdevimab (REGN10987))”
From Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization (2021) · cites this paper as [19]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
MAFFT Multiple Sequence Alignment Software Version 7: Improvements in Performance and Usability
Katoh, K., & Standley, D. M. (2013) · Molecular Biology and Evolution · doi:10.1093/molbev/mst010 · Cited by 46,209
fastp: an ultra-fast all-in-one FASTQ preprocessor
Chen, S., Zhou, Y., Chen, Y., & Gu, J. (2018) · Bioinformatics · doi:10.1093/bioinformatics/bty560 · Cited by 29,721
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897
Structure, function and antigenicity of the SARS-CoV-2 spike glycoprotein
Walls, A. C., Park, Y.-J., Tortorici, M. A., Wall, A., McGuire, A. T., & Veesler, D. (2020) · doi:10.1101/2020.02.19.956581 · Cited by 8,586
Aligning sequence reads, clone sequences and assembly contigs with BWA-MEM
Li, H. (2013) · DROPS (Schloss Dagstuhl – Leibniz Center for Informatics) · doi:10.48550/arxiv.1303.3997 · Cited by 5,159
Aligning sequence reads, clone sequences and assembly con*gs with BWA-MEM
Li, H. (2014) · arXiv (Cornell University) · doi:10.6084/m9.figshare.963153.v1 · Cited by 4,932
Structural basis of receptor recognition by SARS-CoV-2
Shang, J., Ye, G., Shi, K., Wan, Y., Luo, C., Aihara, H., Geng, Q., Auerbach, A., & Li, F. (2020) · Nature · doi:10.1038/s41586-020-2179-y · Cited by 3,661
Snakemake—a scalable bioinformatics workflow engine
Köster, J., & Rahmann, S. (2012) · Bioinformatics · doi:10.1093/bioinformatics/bts480 · Cited by 2,780
Tegally, H., Wilkinson, E., Giovanetti, M., Iranzadeh, A., Fonseca, V., Giandhari, J., Doolabh, D., Pillay, S., San, E. J., Msomi, N., et al. (2020) · doi:10.1101/2020.12.21.20248640 · Cited by 2,535
Detection of a SARS-CoV-2 variant of concern in South Africa
Tegally, H., Wilkinson, E., Giovanetti, M., Iranzadeh, A., Fonseca, V., Giandhari, J., Doolabh, D., Pillay, S., San, E. J., Msomi, N., et al. (2021) · Nature · doi:10.1038/s41586-021-03402-9 · Cited by 2,510
Research works printed but not linked: 2
- 10.1016/j.cell.2020.02.058 · doi:10.1016/j.cell.2020.02.058 · Paper page
- Regeneron Pharmaceuticals Inc. “Regeneron’s casirivimab and imdevimab antibody cocktail for COVID-19 is first combination therapy to receive FDA emergency use authorization ” press release (21 November 2020); https://investor.regeneron.com/news-releases/news-release-details/regenerons-regen-cov2-first-antibody-cocktail-covid-19-receive/.
Cited by
Items 601–700 of 750
El-Kafrawy, S. A., Abbas, A. T., Abdel-dayem, U. A., El-Kafrawy, M. S., & Azhar, E. I. (2026) · Clinical Microbiology Reviews · doi:10.1128/cmr.00249-25 · Cited by 2
“However, their single-epitope specificity can lead to rapid resistance via immune escape mutations, as seen in the diminished efficacy of many SARS-CoV-2 mAbs against emerging variants (19, 20).”
Shao, C., Yang, L., Xiao, C., Huang, Y., Wang, X., Chen, L., Liu, P., Chen, S., Wei, M., 贾斯月, et al. (2026) · Emerging Microbes & Infections · doi:10.1080/22221751.2026.2686472 · Cited by 2
“Meanwhile, the major escape hotspots (escape score > 0.1) were mainly located in the structurally flexible outer loops of the RBM and adjacent regions, overlapping with immunodominant regions targeted by multiple human monoclonal antibodies and polyclonal sera [8,37–42].”
InfluentialSelf-citationCold traps as reliable devices for quantitative determination of SARS-CoV-2 load in aerosols
Gehrke, S. G., Förderer, C., Weiskirchen, R., & Stremmel, W. (2021) · Environmental Monitoring and Assessment · doi:10.1007/s10661-021-09580-3 · Cited by 2
SARS-CoV-2 Variants: Impact of Spike Mutations on Vaccine and Therapeutic Strategies
Raman, R., Patel, K. J., & Ranjan, K. (2022) · Springer eBooks · doi:10.1007/978-3-031-08045-6_7 · Cited by 4
Salimović-Bešić, I., Dedeić-Ljubović, A., Zahirović, E., Hasanović, M., Šehić, M., Vukovikj, M., Boshevska, G., Vegar-Zubović, S., Mehmedika-Suljić, E., & Izetbegović, S. (2022) · Heliyon · doi:10.1016/j.heliyon.2022.e12650 · Cited by 2
“It was shown that the effects of T478K on mAbs and immune plasma retain the binding capacity to each of the EUA-approved mAbs (Starr et al., 2021a, 2021b).”
Rocchigiani, A. M., Ferretti, L., Ledda, A., Nardo, A. D., Floris, M., Bonelli, P., Loi, F., Idda, M. L., Angioi, P. P., Zinellu, S., et al. (2023) · Viruses · doi:10.3390/v15020277 · Cited by 2
The anti-SARS-CoV-2 effect and mechanism of Chiehyuan herbal oral protection solution
Wu, C., Yang, Y., Lin, Y., Shu, L., Cheng, Y., Liu, H.-T., Lin, Y.-Y., Lee, I., Shih, W., Yang, P., et al. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e17701 · Cited by 2
Jin, H., Cheng, L., Gong, Y., Zhu, Y., Chong, H., Zhang, Z., & He, Y. (2023) · Journal of Virology · doi:10.1128/jvi.00192-23 · Cited by 2
Corona-Pandemie: Zukunfts-Überlegungen aus der Sicht epidemiologischer Modellierung
Dürr, P. D. H.-P., & Eichner, P. D. R. N. M. (2022) · Monitor Versorgungsforschung · doi:10.24945/mvf.02.22.1866-0533.2393 · Cited by 2
Genomic analysis of SARS-CoV-2 omicron sublineage BA.5.2.1 in Erbil/ Iraq
Majed, S. O., Jalal, P. J., Fatah, M. H., Karim, K. K., Karim, A., Miasko, M. H., Hasannajad, S., & Mustafa, S. A. (2023) · Cellular and Molecular Biology · doi:10.14715/cmb/2023.69.11.10 · Cited by 2
Computational Modeling Insights into Extreme Heterogeneity in COVID-19 Nasal Swab Data
Zhang, L., Cao, H., Medlin, K., Pearson, J., Aristotelous, A. C., Chen, A. J., Wessler, T., & Forest, M. G. (2023) · Viruses · doi:10.3390/v16010069 · Cited by 2
Application of Omics and Bioinformatics Technologies in Response to COVID-19 Pandemic
Aga, A. M., & Woldesemayat, A. A. (2024) · Molecular and Cellular Biomedical Sciences · doi:10.21705/mcbs.v8i1.363 · Cited by 2
Somatic hypermutation shapes the viral escape profile of SARS-CoV-2 neutralising antibodies
Bruhn, M., Obara, M., González-Hernández, M., Reineking, W., Salam, M. A., Mirolo, M., Hinrichs, I., Mergani, A., Bartsch, Y. C., Schambach, A., et al. (2025) · EBioMedicine · doi:10.1016/j.ebiom.2025.105770 · Cited by 4
Development and characterization of SARS-CoV-2 variant-neutralizing monoclonal antibodies
Qiu, H., Yuan, X.-Y., Cabral, T. M., Manguiat, K., Robinson, A., Wood, H., Grant, C., McQueen, P., Westmacott, G., Beniac, D. R., et al. (2021) · Antiviral Research · doi:10.1016/j.antiviral.2021.105206 · Cited by 4
Nomura, T., Kitagawa, H., Kakimoto, M., Kaiki, Y., Nazmul, T., Miyamori, D., Omori, K., Shigemoto, N., Ito, M., Sakaguchi, T., et al. (2022) · Journal of Infection and Chemotherapy · doi:10.1016/j.jiac.2022.03.013 · Cited by 2
“Furthermore, it has been reported that viral mutations may reduce the efficacy of antibody-based therapies such as REGN-CoV2 [7,8].”
Effect on the conformations of the spike protein of SARS‐CoV‐2 due to mutation
Gupta, A. M., & Chakrabarti, J. (2022) · Biotechnology and Applied Biochemistry · doi:10.1002/bab.2413 · Cited by 2
Zhao, D., Wang, X., Liu, J., Chinnappa, A. U., Basavaraj, V., Sri, C. D., Nikolenko, V. N., Beeraka, N. M., Shivaprakash, P., & Fan, R. (2023) · Current Pharmaceutical Biotechnology · doi:10.2174/1389201024666230227115329 · Cited by 3
Shelton, P. M. M., & Kapoor, T. M. (2021) · Nature Chemical Biology · doi:10.1038/s41589-021-00897-1 · Cited by 2
Lin, C., Fang, T., Chen, J., Li, Q., Yang, W., Yao, C., Wang, L., Sun, Y., Cai, Z., Ping, J., et al. (2022) · PubMed · Cited by 2
Wang, H., Yang, T., Jiang, W., Qin, M., Sun, Z., Dai, W. H., & Jiang, Y. (2022) · Scientific Reports · doi:10.1038/s41598-022-19886-y · Cited by 2
Laefer, D. F., Kirchner, T., Haoran, Jiang, Cheong, D., Yunqi, Jiang, Khan, A., Qiu, W., Tai, N., et al. (2021) · arXiv (Cornell University) · doi:10.48550/arxiv.2101.10079 · Cited by 2
Potent and pan-neutralization of SARS-CoV-2 variants of concern by DARPinsPreprint
Chonira, V., Kwon, Y. D., Gorman, J., Case, J. B., Ku, Z., Simeon, R. L., Casner, R. G., Harris, D. R., Olia, A. S., Stephens, T., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.05.30.493765 · Cited by 2
Deep mutational scanning of whole SARS-CoV-2 spike in an inverted infection systemPreprint
Taminishi, S., Li, S., Higuchi, Y., Kirita, Y., Motooka, D., Ozaki, Y., Arimori, T., Ikemura, N., Itoh, Y., Matoba, S., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.07.17.549430 · Cited by 2
Karim, F., Bernstein, M. P., Jule, Z., Lustig, G., Upton, J., Ganga, Y., Khan, K., Reedoy, K., Mazibuko, M., Govender, K., et al. (2023) · medRxiv · doi:10.1101/2023.08.18.23293746 · Cited by 2
Ketaren, N. E., Mast, F. D., Fridy, P. C., Olivier, J. P., Sanyal, T., Šali, A., Chait, B. T., Rout, M. P., & Aitchison, J. D. (2023) · eLife · doi:10.7554/elife.89423.1 · Cited by 3
Mahmoud, Y., Hathout, A., Amen, R. A., Desouky, S., Shady, R. M., & Fahmy, H. M. (2023) · Reviews in Medical Microbiology · doi:10.1097/mrm.0000000000000386 · Cited by 1
“Reduced Omicron neutralization relative to prototypes and other VOCs could be connected to Spike protein mutations E484A and K417N [79,80,81].”
(2025) · doi:10.1371/journal.pone.0299440 · Cited by 1
Feng, S., Huang, M., Quan, Y., Sun, L., Lin, J., Zhang, D., Wei, X., Wang, Z., Ma, X., Wang, S., et al. (2025) · Virology · doi:10.1016/j.virol.2025.110612 · Cited by 1
Egress-enhancing mutation reveals the inefficiency of non-enveloped virus cell exit
Rodriguez-Irizarry, V. J., Maples, R. W., & Pfeiffer, J. K. (2025) · PLoS Biology · doi:10.1371/journal.pbio.3003245 · Cited by 1
“Adaptive mutations can enhance viral replication under various selective pressures, including neutralizing antibodies [8], replication within animals [9], and heat exposure [10].”
Idowu, K. A., Widmann, S., & Olaleye, E. O. (2025) · Computational and Structural Biotechnology Reports · doi:10.1016/j.csbr.2025.100067 · Cited by 1
Jung, I., Sriramulu, D. K., Lee, S., & Jung, S. T. (2025) · ACS Synthetic Biology · doi:10.1021/acssynbio.5c00425 · Cited by 1
“34,35 − 38 Nevertheless, IJ36-V possesses a structurally well-defined and modular interface, providing a versatile scaffold for adapting antigen specificity in response to viral variation.”
Zhou, Y., & Wang, T. (2025) · The Journal of Chemical Physics · doi:10.1063/5.0300029 · Cited by 1
Synthetic RNA–protein decoy granules prevent SARS-CoV-2 infection
Willinger, O., Granik, N., Nelkin, A., Salomon, T., Goldberg, S., & Amit, R. (2026) · Trends in biotechnology · doi:10.1016/j.tibtech.2026.02.017 · Cited by 1
Wang, Q., Li, H., Jian, F., Han, A., Liu, Y., Liu, J., Yu, Y., Wang, J., Yu, L., Wang, Y., et al. (2026) · Cell Reports · doi:10.1016/j.celrep.2026.117248 · Cited by 1
Mariani, M. G. E. (2026) · Theory in Biosciences · doi:10.1007/s12064-026-00469-8 · Cited by 1
“A more recent study by Starr et al. (2021) used fluorescence-activated cell sorting (FACS) and deep sequencing to analyse the receptor-binding domain (RBD) of SARS-CoV-2.”
Taylor, A. L., & Starr, T. N. (2026) · PLoS Pathogens · doi:10.1371/journal.ppat.1014074 · Cited by 2
Self-citationPriyadarshi, H., & Das, R. (2021) · Theory in Biosciences · doi:10.1007/s12064-021-00349-3 · Cited by 1
Khodosh, E. M., Ивахно, И. В., Efremova, O. A., Obolonkova, N. I., Голивец, Т. П., & Khamnagadaev, I. I. (2022) · Актуальные проблемы медицины · doi:10.52575/2687-0940-2022-45-1-39-54 · Cited by 1
Phenogenomics of Mycobacterium abscessus
Comas, I., & Moreno-Molina, M. (2022) · Nature Microbiology · doi:10.1038/s41564-022-01217-6 · Cited by 1
Polarimetric imaging for the detection of synthetic models of SARS-CoV-2: A proof of concept
Gómez-González, E., Muñoz, O., Martín, J. C. G., Aceituno-Castro, J., Fernández‐Muñoz, B., Navas-Garcia, J. M., Barriga‐Rivera, A., Fernández-Lizaranzu, I., Munoz-Gonzalez, F. J., Giráldez, R. P., et al. (2023) · Journal of Quantitative Spectroscopy and Radiative Transfer · doi:10.1016/j.jqsrt.2023.108567 · Cited by 1
Shen, H., & Yang, H. (2023) · Physical Chemistry Chemical Physics · doi:10.1039/d3cp02628k · Cited by 1
Mammalian Antigen Display for Pandemic Countermeasures
Quezada, A., Annapareddy, A., Javanmardi, K., Cooper, J., & Finkelstein, I. J. (2024) · Methods in molecular biology · doi:10.1007/978-1-0716-3666-4_12 · Cited by 1
Agostini, M. L., Schnell, G., di Iulio, J., Kohli, A., Shapiro, A. E., Sarkis, E. H., Givens, N., Peppercorn, A., Skingsley, A., Gaffney, L. A., et al. (2024) · Future Virology · doi:10.1080/17460794.2024.2350923 · Cited by 1
Matsuzaka, Y., & Yashiro, R. (2024) · BioMedInformatics · doi:10.3390/biomedinformatics4020084 · Cited by 1
“If this mutant virus is not recognized as pathogenic by antibodies produced during a previous infection, individuals who have been infected once can also become infected [15–17].”
BackgroundSARS-CoV-2 variant replacement constrains vaccine-specific viral diversification
Dearlove, B. L., Fries, A. C., Epsi, N. J., Richard, S. A., Ganesan, A., Huprikar, N., Lindholm, D. A., Mende, K., Colombo, R. E., Colombo, C. J., et al. (2024) · Virus Evolution · doi:10.1093/ve/veae071 · Cited by 1
A proposed workflow for proactive virus surveillance and prediction of variants for vaccine design
Baker, J. J., Mathy, C. J. P., & Schaletzky, J. (2021) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1009624 · Cited by 1
The emergence of COVID-19 vaccine resistance depends on human choices
(2022) · Nature Human Behaviour · doi:10.1038/s41562-022-01313-x · Cited by 1
Ходош, Э. М., & Ivakhno, I. V. (2022) · EMERGENCY MEDICINE · doi:10.22141/2224-0586.18.3.2022.1484 · Cited by 1
Antony, P., Jobe, A., & Vijayan, R. (2022) · PeerJ · doi:10.7717/peerj.13680 · Cited by 1
“Laurini et al. (2021) reported an interface stabilizing effect of the Q493K mutation, and immune evasion through monoclonal antibody neutralization was documented by Starr et al. (2021) ( Laurini et al., 2021 ).”
Inder, D., Manak, S., Akram, M. F., & Kumar, P. (2022) · Saudi Journal for Health Sciences · doi:10.4103/sjhs.sjhs_42_22 · Cited by 1
The Covid Calamity, the Human Life, and the Surviving Hope
Nikhra, V. (2021) · Virology & Immunology Journal · doi:10.23880/vij-16000275
Ferrara, F., D’Angelo, S., Erasmus, M. F., Teixeira, A. A. R., Leal‐Lopes, C., Spector, L. P., Pohl, T., Fanni, A. M., Cocklin, S., & Bradbury, A. M. (2022) · mAbs · doi:10.1080/19420862.2022.2133666 · Cited by 2
Endogenous antibody responses in REGN-COV2-treated SARS-CoV-2-infected individuals
Kurshan, A., Snell, L. B., Prior, L., Tam, J. C. H., Graham, C., Thangarajah, R., Edgeworth, J. D., Nebbia, G., & Doores, K. J. (2023) · Oxford Open Immunology · doi:10.1093/oxfimm/iqac012 · Cited by 1
Analysis of Sars-CoV-2 RBD Mutations in Khuzestan Province, Iran - A Retrospective Study, 2021
Beheshti, M., Neisi, N., Parsanahad, M., Rasti, M., & Pirmoradi, R. (2023) · Iranian Journal of Medical Microbiology · doi:10.30699/ijmm.17.2.194 · Cited by 1
Chiara, M., Horner, D. S., Ferrandi, E., Gissi, C., & Pesole, G. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.06.23.449558 · Cited by 1
Viral population genomics reveals host and infectivity impact on SARS-CoV-2 adaptive landscapePreprint
Gayvert, K. M., Copin, R., McKay, S., Setliff, I., Lim, W. K., Baum, A., Kyratsous, C. A., & Atwal, G. S. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.12.30.474516 · Cited by 1
Tang, H., Ke, Y., Ma, H., Han, L., Wang, L., Zong, H., Yuan, Y., Wang, Z., He, Y., Chang, Y., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.01.17.475291 · Cited by 2
WITHDRAWNPreprint
Datta, S. (2021) · ChemRxiv · doi:10.26434/chemrxiv-2021-l393t-v35 · Cited by 1
Weidenbacher, P. A. B., Waltari, E., Kobara, I. D. L. R., Bell, B. N., Pak, J. E., & Kim, P. S. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.01.24.477625 · Cited by 1
Chen, C., Saville, J. W., Martí, M. M., Schäfer, A., Cheng, M. H., Mannar, D., Zhu, X. Q., Berezuk, A., Banerjee, A., Sobolewski, M. D., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.02.18.481058 · Cited by 1
Omicron BA.2 (B.1.1.529.2): high potential to becoming the next dominating variant.Preprint
Chen, J., & Wei, G. (2022) · PubMed · Cited by 3
WITHDRAWNPreprint
Datta, S. (2021) · ChemRxiv · doi:10.26434/chemrxiv.13102877.v30 · Cited by 1
WITHDRAWNPreprint
Datta, S. (2021) · ChemRxiv · doi:10.26434/chemrxiv-2021-l393t-v33 · Cited by 1
SARS-CoV-2 evolution and evasion from multiple antibody treatments in a cancer patientPreprint
Shapira, G., Weiner, C., Sorek‐Abramovich, R., Gutwein, O., Rainy, N., Benveniste‐Levkovitz, P., Gordon, E., Chaim, A. B., & Shomron, N. (2022) · medRxiv · doi:10.1101/2022.06.25.22276445 · Cited by 1
Raiser, F., Davis, M., Adelglass, J. M., Cai, M. R., Chau, G., Cloney-Clark, S., Eickhoff, M., Kalkeri, R., McKnight, I., Plested, J. S., et al. (2023) · medRxiv · doi:10.1101/2023.03.16.23287030 · Cited by 1
Ketaren, N. E., Mast, F. D., Fridy, P. C., Olivier, J. P., Sanyal, T., Sali, A., Chait, B. T., Rout, M. P., & Aitchison, J. D. (2023) · doi:10.1101/2023.07.14.549041 · Cited by 1
Zhang, L., Cao, H., Medlin, K., Pearson, J., Aristotelous, A. C., Chen, A. J., Wessler, T., & Forest, M. G. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.11.04.565660 · Cited by 1
Inadvertent Human Mucosal Exposure to SARS-CoV-2 Recombinant S1 Protein Elicits ImmunityPreprint
Carbonell (2021) · Research Square · doi:10.21203/rs.3.rs-249113/v1
WITHDRAWNPreprint
Datta, S. (2021) · ChemRxiv · doi:10.26434/chemrxiv.13102877.v32 · Cited by 1
Discovery of nanobodies against SARS-CoV-2 and an uncommon neutralizing mechanismPreprint
Li, T., Zhou, B., Luo, Z., Lai, Y., Huang, S., Zhou, Y., Gautam, A., Bourgeau, S., Wang, S., Bao, J., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.07.20.453054
A bacteria-based assay to study SARS-CoV-2 protein-protein interactionsPreprint
Springstein, B. L., Deighan, P., Grabe, G., & Hochschild, A. (2021) · bioRxiv · doi:10.1101/2021.10.07.463611
Ręka, G., Pawlak, A., Machowiec, P. A., Maksymowicz, M., & Piecewicz‐Szczęsna, H. (2021) · Current Issues in Pharmacy and Medical Sciences · doi:10.2478/cipms-2021-0030
Datta, S. (2021) · doi:10.33774/chemrxiv-2021-l393t-v35
Verkhivker, G. M., Agajanian, S., Kassab, R., & Krishnan, K. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.12.09.471953
Chan, C. E.-Z., Ng, C.-G., Lim, A. P.-C., Seah, S. G. K., Chye, D. H., Wong, S. K. K., Lim, J.-H., Lim, V. Z.-Y., Lai, S.-K., Wong, P.-S., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.12.06.471528
Engineering SARS-CoV-2 neutralizing antibodies for increased potency and reduced viral escapePreprint
Zhao, F., Keating, C., Ozorowski, G., Shaabani, N., Francino-Urdaniz, I. M., Barman, S., Limbo, O., Burns, A., Zhou, P.-P., Ricciardi, M. J., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.01.06.475303
WITHDRAWNPreprint
Datta, S. (2021) · ChemRxiv · doi:10.26434/chemrxiv.13102877.v31
Datta, S. (2021) · doi:10.33774/chemrxiv-2021-l393t-v33 · Cited by 1
Zhang, L., Domeniconi, G., & Yang, C.-C. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.02.17.480939
Evolutionary safety of death by mutagenesisPreprint
Lobinska, G., Pilpel, Y., & Nowak, M. A. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.03.10.483790
Datta, S. (2021) · doi:10.33774/chemrxiv-2021-l393t-v36 · Cited by 1
Rochman, N. D., Faure, G., Wolf, Y. I., Freddolino, P. L., Zhang, F., & Koonin, E. V. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3945930
WITHDRAWNPreprint
Datta, S. (2021) · ChemRxiv · doi:10.26434/chemrxiv.13102877.v28
WITHDRAWNPreprint
Datta, S. (2021) · ChemRxiv · doi:10.26434/chemrxiv.13102877.v29
WITHDRAWNPreprint
Datta, S. (2021) · ChemRxiv · doi:10.26434/chemrxiv-2021-l393t-v34
WITHDRAWNPreprint
Datta, S. (2021) · ChemRxiv · doi:10.26434/chemrxiv.13102877.v27
Datta, S. (2021) · doi:10.33774/chemrxiv-2021-l393t-v34
Uncovering the structural flexibility of SARS-CoV-2 glycoprotein spike variantsPreprint
Arruda, H. R. S., Lima, T. M., Alvim, R. G. F., Victorio, F. B. A., de Abreu, D. P. B., Marsili, F. F., Cruz, K. D., Sosa‐Acosta, P., Quiñones‐Vega, M., Guedes, J. D. S., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.04.20.488873
Kastenhuber, E. R., Johnson, J. L., Yaron, T. M., Mercadante, M. N., & Cantley, L. C. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.06.16.496428
Sandhya, K. S., & Nair, A. S. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4115160
Bailey, S. F., & Akter, M. (2022) · Springer eBooks · doi:10.1007/978-981-19-1356-3_5
Uncovering hidden sources of SARS‐CoV‐2 viral evolution: A call to action
Choudhary, M. C., & Li, J. Z. (2022) · Transplant Infectious Disease · doi:10.1111/tid.13910
Self-citationBhattacharyya, S. (2022) · Trends in Sciences · doi:10.48048/tis.2022.5768
Graph-based system for predictive epidemiological surveillancePreprint
Akagi, J. T., García-Torres, M., Pérez-Estigarribia, P. E., Bernal, D. A. F., Grillo, S. A., Mello-Román, J. C., Noguera, J. L. V., Muñóz, M., Pedrozo, M. E., Cabrera, S. V. I., et al. (2022) · Research Square · doi:10.21203/rs.3.rs-1795250/v1
Deep mutational scanning to predict antibody escape in SARS-CoV-2 Omicron subvariantsPreprint
Alcantara, M. C., Higuchi, Y., Kirita, Y., Matoba, S., & Hoshino, A. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.12.02.518937
Agnihotri, S., Mehta, A., & Sharma, A. (2023) · COVID · doi:10.3390/covid3020018
López-Morales, J., Vanella, R., Utzinger, T., Schittny, V., Hirsiger, J. R., Osthoff, M. F., Berger, C. T., Guri, Y., & Nash, M. A. (2023) · medRxiv · doi:10.1101/2023.02.17.23286074
Development of broadly reactive antibody therapeutics for SARS-CoV-2
Moriyama, S. (2022) · Drug Delivery System · doi:10.2745/dds.37.388
SARS-CoV-2: Structure, Pathogenesis, and Diagnosis
Goverdhan, A. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-87539-4.00002-6 · Cited by 2
Metadata
- Authors
- Starr, T. N., Greaney, A. J., Addetia, A., Hannon, W. W., Choudhary, M. C., Dingens, A. S., Li, J. Z., & Bloom, J. D.
- Affiliations
- Fred Hutch Cancer Center (US)
- University of Washington (US)
- Brigham and Women's Hospital (US)
- Howard Hughes Medical Institute (US)
- Corresponding author
- Bloom, Jesse D.
- ORCID
- Venue
- Science
- Published
- 2021-02-19
- Volume
- 371
- Issue
- 6531
- Pages
- 850-854
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC7963219
- OpenAlex
- W3125266951
- Cited by
- 743
- References
- 40
- Citations by year
- 2026: 31 · 2025: 37 · 2024: 56 · 2023: 104 · 2022: 232 · 2021: 279
- FWCI
- 53.32
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Science (publishedVersion, cc-by)
- bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- PubMed Central (submittedVersion, cc-by)
- Funders
- Howard Hughes Medical Institute (Investigator)
- National Institute of Allergy and Infectious Diseases (R01AI127893, R01AI141707)
- Bill and Melinda Gates Foundation (INV-004949)
- Damon Runyon Cancer Research Foundation (DRG-2381-19)
- Massachusetts Consortium for Pathogen Readiness
- Washington Research Foundation (Innovation Fellow)
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › vaccines and immunoinformatics approaches
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 detection and testing
- Keywords
- SARS-CoV-2, COVID-19 pandemic, antibody escape, receptor binding domain, viral mutations, monoclonal antibodies, antibody binding, viral surveillance
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.